Skip to main content

Table 3 Treatment-related AEs experienced by at least 2% of patients aged > 70 or ≤ 70 years

From: Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

  Patients aged > 70 years (n = 193), n(%) Patients aged ≤ 70 years (n = 662), n(%)
Treatment-related AEs experienced by at least 2% of patients Any grade Grade III–IV Any grade Grade III–IV
Pruritus 11 (6) 0 47 (7) 1 (<1)
Rash 19 (10) 1 (<1) 45 (7) 3 (<1)
Diarrhoea 9 (5) 2 (1) 51 (8) 17 (3)
Nausea 5 (3) 0 42 (6) 2 (<1)
Liver toxicity 3 (2) 2 (1) 16 (2) 13 (2)
  1. AEs, adverse events.